TY - JOUR
T1 - Recent advances in adjuvant therapy for breast cancer
AU - Palmieri, Frances M.
AU - Perez, Edith A.
PY - 2003
Y1 - 2003
N2 - OBJECTIVES: To review recent studies that may influence the adjuvant treatment of patients with breast cancer. Studies reviewed evaluate the role of aromatase inhibitors, incorporation of taxanes into chemotherapy regimens, novel dosage schedules, and supportive care with epoetin alfa. DATA SOURCES: Published literature and clinical experience. CONCLUSION: Recent evidence suggests that aromatase inhibitors are more effective than tamoxifen as hormonal adjuvant therapy and that the addition of taxanes to adjuvant chemotherapy improves outcome. Supportive care is also an important component of therapy. IMPLICATIONS FOR NURSING PRACTICE: Knowledge of recent advances in adjuvant therapy for breast cancer will contribute to greater efficacy in patient care.
AB - OBJECTIVES: To review recent studies that may influence the adjuvant treatment of patients with breast cancer. Studies reviewed evaluate the role of aromatase inhibitors, incorporation of taxanes into chemotherapy regimens, novel dosage schedules, and supportive care with epoetin alfa. DATA SOURCES: Published literature and clinical experience. CONCLUSION: Recent evidence suggests that aromatase inhibitors are more effective than tamoxifen as hormonal adjuvant therapy and that the addition of taxanes to adjuvant chemotherapy improves outcome. Supportive care is also an important component of therapy. IMPLICATIONS FOR NURSING PRACTICE: Knowledge of recent advances in adjuvant therapy for breast cancer will contribute to greater efficacy in patient care.
UR - http://www.scopus.com/inward/record.url?scp=1342288106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1342288106&partnerID=8YFLogxK
U2 - 10.1053/j.soncn.2003.09.004
DO - 10.1053/j.soncn.2003.09.004
M3 - Article
C2 - 14702916
AN - SCOPUS:1342288106
SN - 0749-2081
VL - 19
SP - 10
EP - 16
JO - Seminars in Oncology Nursing
JF - Seminars in Oncology Nursing
IS - SUPPL. 2
ER -